Price Alert

Twist Bioscience Corporat... (TWST)

NASDAQ: TWST · Real-Time Price · USD

26.97

0.38 (1.43%)

At close: Aug 29, 2025, 3:59 PM

26.60

-1.37%

After-hours: Aug 29, 2025, 07:12 PM EDT

1.43% (1D)

Bid	26.6
Market Cap	1.63B
Revenue (ttm)	362.27M
Net Income (ttm)	-85.19M
EPS (ttm)	-1.44
PE Ratio (ttm)	-18.73
Forward PE	-20.43
Analyst	Buy

Ask	26.95
Volume	1,199,842
Avg. Volume (20D)	1,327,060
Open	26.58
Previous Close	26.59
Day's Range	26.22 - 27.06
52-Week Range	24.28 - 55.33
Beta	2.37

About TWST

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TWST

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TWST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Twist Bioscience Corporation is scheduled to release its earnings on Nov 17, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 weeks ago

-10.3%

Twist Bioscience shares are trading lower after th... Unlock content with Pro Subscription

4 months ago

-8.44%

Twist Bioscience shares are trading lower after the company reported a Q2 EPS miss.

News

5 days ago · seekingalpha.com

mRNA Biotechs - Long-Term Value Risks Abound

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...

1 week ago · businesswire.com

Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launche...

2 weeks ago · seekingalpha.com

Twist Bioscience: Headwinds Are Mounting

Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also...

3 weeks ago · zacks.com

After Plunging 33.8% in 4 Weeks, Here's Why the Trend Might Reverse for Twist Bioscience (TWST)

The heavy selling pressure might have exhausted for Twist Bioscience (TWST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street an...

3 weeks ago · businesswire.com

Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of direct...

4 weeks ago · benzinga.com

Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings

What if a biotech company could flip its financial narrative from loss to profit in just a year? Twist Bioscience Corporation TWST has done just that, reporting a surprising third-quarter income that ...

4 weeks ago · seekingalpha.com

Twist Bioscience Corporation (TWST) Q3 2025 Earnings Call Transcript

Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Adam Laponis - Chief Financial Officer Angela Bitting - Chief Corporate Resp...

4 weeks ago · zacks.com

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.86 per share a year ago.

4 weeks ago · businesswire.com

Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter...

1 month ago · businesswire.com

Twist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Load More News